Last reviewed · How we verify
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
Details
| Lead sponsor | University of Washington |
|---|---|
| Phase | PHASE2 |
| Status | TERMINATED |
| Enrolment | 18 |
| Start date | Fri Aug 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jun 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- ATM Gene Mutation
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Homologous Recombination Deficiency
- Prostate Carcinoma Metastatic in the Bone
- PSA Level Greater Than or Equal to Two
- PSA Progression
- Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
- Carboplatin
- Docetaxel
- Laboratory Biomarker Analysis
- Rucaparib Camsylate
- Rucaparib
Countries
United States